In a groundbreaking achievement, Inno Medicine has developed an innovative targeted therapy of atherosclerosis, resulting from a successful technology transfer collaboration with Beijing Anzhen Hospital. This remarkable advancement enables precise and effective treatment of atherosclerosis by employing a unique active targeting delivery system, ensuring the drug reaches the intended site to deliver its therapeutic benefits. YN001 has received IND approval from the US FDA and China NMPA, becoming the world's first cardiovascular targeted drug to enter clinical trials, is expected to become the first cardiovascular drug in history to obtain FDA approval through Accelerated Approval, and become a disruptive treatment method in this field. The project has been granted by the National 14th Five-Year Key Research and Development Program of China, and has obtained funding support from multiple research projects from the National Natural Science Foundation of China and the Beijing Natural Science Foundation.